{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["103"],"submitter":["Taradeh M"],"funding":["INSERM","Sorbonne Université","Société Francophone du Diabète","Alliance Sorbonne Université","French National Research Agency","Fondation de France","Fondation pour la Recherche Médicale"],"pubmed_abstract":["<h4>Aims</h4>Low plasma high-density lipoprotein (HDL)-cholesterol levels are associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), potentially reflecting impaired antiatherogenic HDL functions. These latter are strongly influenced by the HDL phospholipidome, which is frequently altered in ASCVD patients. Several studies reported that plasma levels of phosphatidylethanolamine (PE) species, particularly PE (36:5), were positively associated with ASCVD, but the underlying mechanisms remain unclear. Plasma PE (36:5) exists as eicosapentaenoic (EPA)-PE and arachidonic acid (ARA)-PE, with the latter predominating in ASCVD. This study investigated whether the association of PE (36:5) with ASCVD might result from an impairment of the antiatherogenic functions of HDL.<h"],"journal":["Molecular metabolism"],"pagination":["102281"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12703979"],"repository":["biostudies-literature"],"pubmed_title":["Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases."],"pmcid":["PMC12703979"],"pubmed_authors":["Hardy LM","Lhomme M","Pais-De-Barros JP","Le Goff W","Frisdal E","Bruckert E","Materne C","Wang H","Kc P","Guillas I","Reydellet C","Ponnaiah M","Gallo A","Kontush A","Bun E","Dahik VD","Kappeler L","Galier S","Durand H","Clemessy M","Masson D","El Khoury P","Lesnik P","Giral P","Guerin M","Villard EF","Taradeh M"],"additional_accession":[]},"is_claimable":false,"name":"Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases.","description":"<h4>Aims</h4>Low plasma high-density lipoprotein (HDL)-cholesterol levels are associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), potentially reflecting impaired antiatherogenic HDL functions. These latter are strongly influenced by the HDL phospholipidome, which is frequently altered in ASCVD patients. Several studies reported that plasma levels of phosphatidylethanolamine (PE) species, particularly PE (36:5), were positively associated with ASCVD, but the underlying mechanisms remain unclear. Plasma PE (36:5) exists as eicosapentaenoic (EPA)-PE and arachidonic acid (ARA)-PE, with the latter predominating in ASCVD. This study investigated whether the association of PE (36:5) with ASCVD might result from an impairment of the antiatherogenic functions of HDL.<h","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-06T03:42:08.92Z","creation":"2026-05-25T03:08:07.217Z"},"accession":"S-EPMC12703979","cross_references":{"pubmed":["41248752"],"doi":["10.1016/j.molmet.2025.102281"]}}